Company has initiated Phase 1 study with STRO-004, its potential best-in-class Tissue Factor ADC - - Sutro has selected PTK7 as the target for ...
Gynecological cancers remain a major threat to women's health, with traditional therapies often having limited effect and ...
The FDA has granted fast track designation to the EGFR/HER3 bispecific antibody-drug conjugate (ADC) AVZO-1418 for treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback